Stoke Therapeutics' (STOK) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $24.00 target price on the stock.

A number of other analysts have also recently weighed in on STOK. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. HC Wainwright boosted their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $23.00.

Stoke Therapeutics Stock Down 2.2 %

Shares of NASDAQ STOK traded down $0.18 during midday trading on Wednesday, reaching $8.15. 1,407,236 shares of the company were exchanged, compared to its average volume of 839,852. The stock's 50-day moving average price is $9.47 and its 200-day moving average price is $11.39. The stock has a market cap of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a one year low of $6.29 and a one year high of $17.58.

Remove Ads

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities research analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 over the last quarter. Company insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at about $63,000. Teacher Retirement System of Texas bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at approximately $113,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at approximately $124,000. Tower Research Capital LLC TRC grew its position in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at approximately $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.